Prostate cancer consultations are common in primary care and there is no one approach to testing and treatment that fits all patients. Urologist Simon van Rij discusses the key considerations and options for personalised care, appropriate investigation and treatment
At the heart of new antidiabetic agents lies hope for delaying the onset of CVD
+Print Archive
Pathology Update
At the heart of new antidiabetic agents lies hope for delaying the onset of CVD
Wednesday 22 May 2019, 07:00 AM
More change is ahead in diabetes treatment, including improving cardiovascular outcomes for more patients, says Australian expert Jonathan Shaw
The fifth and final article in a series from Pathology Update 2019, this year’s conference of the Royal College of Pathologists of Australasia. Virginia McMillan attended as a guest of the college
Glycaemic targets may be relaxed. If a drug will reduce cardiovascular and renal risk, “what is the point of pushing HbA1c from above 7.5 per cent to
References
3. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes N Engl J Med 2015; 373:2117–2128. doi: 10.1056/NEJMoa1504720
5. Wiviott SD, Raz I, Bonaca MP et al. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med 2019; 380:347-357. DOI: 10.1056/NEJMoa1812389